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Abstract   
Introduction.  Few studies have evaluated exercise interventions for smokers with depression or 
other psychiatric comorbidities. This pilot study evaluated the potential role of supervised 
vigorous exercise as a smoking cessation intervention for depressed females.  
Methods.  Thirty adult women with moderate-severe depressive symptoms were enrolled and 
randomly assigned to 12 weeks of thrice weekly, in person sessions of vigorous intensity 
supervised exercise at a YMCA setting (EX; n=15) or health education (HE; n=15).   All 
participants received behavioral smoking cessation counseling and nicotine patch therapy. 
Assessments were done in person at baseline, at the end of 12 weeks of treatment, and at 6 
months post target-quit-date.  Primary endpoints were exercise adherence (proportion of 36 
sessions attended) and biochemically confirmed 7-day point prevalence abstinence at Week 12.  
Biomarkers of inflammation were explored for differences between treatment groups and 
between women continuing to smoke and those who quit at Week 12. 
Results.  Treatment adherence was high for both groups (66% for HE and 72% for EX; p=0.55).   
The week 123 smoking abstinence rate was higher for EX than HE (11/15 [73%] vs. 5/15 [33%]; 
p=0.028), but no significant differences emerged at 6-month follow-up.  Interlukin (IL6) levels 
increased more for smokers compared with those abstinent at Week 12 (p=0.040).  
Conclusions. Vigorous intensity supervised exercise is feasible and enhances smoking cessation 
among depressed female smokers. Innovative and cost-effective strategies to bolster long-term 
exercise adherence and smoking cessation need evaluation in this population.  Inflammatory 
biomarkers could be examined in future research as mediators of treatment efficacy.
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Implications 
This preliminary study found that vigorous intensity supervised exercise is feasible and enhances 
smoking cessation among depressed female smokers. This research addressed an important gap 
in the field. Despite decades of research examining exercise interventions for smoking cessation, 
few studies were done among depressed smokers or those with comorbid psychiatric disorders. A 
novel finding was increases in levels of a pro-inflammatory biomarker observed among women 
who continued to smoke after the intervention compared to those who did not. 
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Introduction 
In 2014, the prevalence of cigarette smoking among United States women was 14.8%.1 Women 
have lower quit rates than men.2,3 Also, women smokers tend to have higher levels of depression 
than non-smokers4 and smokers with elevated depressive symptoms have poorer smoking 
treatment outcomes.5-7 Thus, designing effective smoking cessation interventions for women 
with depression – a tobacco use disparity group – is a public health priority.8,9 Few studies have 
targeted smokers with current depression and, aside from our pilot study,10 none of these targeted 
women specifically.11-15 This pilot study evaluated the potential role of supervised vigorous 
exercise as a smoking cessation intervention for depressed females.  
A recent Cochrane review of 20 randomized trials concluded there was little evidence 
that exercise was effective as a smoking cessation intervention.16  These trials were limited by 
small sample sizes, inadequate control groups, interventions of insufficient exercise intensity, 
and a lack of support being provided to ensure adherence to the exercise intervention. The only 
trial to show a long-term effect on smoking abstinence targeted women using 12-weeks of thrice 
weekly, supervised vigorous intensity exercise;17 an intervention also effective for treating 
depression.18 When this treatment was translated to a community YMCA setting and streamlined 
to four supervised exercise sessions, it was not effective for smoking cessation and there was 
poor adherence to exercise.19 Similarly, two studies of exercise counseling encouraging home-
based exercise for depressed smokers found no effect on smoking abstinence compared with a 
health education contact control group.10,11  
A supervised exercise program has the potential to benefit depressed smokers by 
providing reinforcement, guidance, and support for exercise; thus improving adherence.16 In this 
study we piloted the feasibility, acceptability and potential efficacy of a supervised, vigorous 
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intensity exercise intervention for smoking cessation in a community YMCA setting among 
depressed females. An exploratory aim was to examine potential biological impact of treatment 
response, through assessment of the intervention (exercise), and smoking cessation outcome on 
biomarkers of inflammation.  
Methods 
The study was approved by the Mayo Clinic Institutional Review Board, and registered with 
clinicaltrials.gov (NCT01860924). Data were collected from September, 2013-April, 2015.  
Participants 
A sample size of 30 was deemed sufficient to determine the intervention’s feasibility with 
respect to adherence to the exercise treatment protocol.20-22 The study was not powered to detect 
significant differences in smoking abstinence rates, but we sought to obtain estimates of the 
intervention effect towards planning a definitive trial. A doubling of the abstinence rate for the 
intervention vs. control condition at end-of-treatment was considered to be of clinical 
significance and warrant proceeding to an efficacy trial.23  
Participants were recruited by provider referrals and flyers posted in the clinic, and radio 
and newspaper advertisements. Initial screening was completed by telephone. Eligible women 
were asked to complete an in-person screening assessment. After obtaining written informed 
consent, the study coordinator administered the MINI International Neuropsychiatric Interview,24 
to rule out bipolar and thought disorders. Participants then completed a urine pregnancy test and 
provided height and weight. 
If eligible, individuals completed a baseline self-report questionnaire and exercise 
testing.25 Potential participants received the Modular Signal Recorder (MSR) accelerometer to 
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wear for at least four days and return in a pre-paid envelope. If the MSR was returned, the 
participant was enrolled.  
Eligibility criteria were: female, aged 18-55 years, smoked > 10 cigarettes a day for at 
least the past year, willing to make a quit attempt, currently depressed defined by a clinical cut-
off score of >16 on the 10-item Center for Epidemiological Studies Depression Scale 
corresponding to moderate-severe depression (CES-D),26 not currently meeting the ACSM 
guidelines for exercise,27 willing and able to participate in all aspects of the study, provide 
written informed consent, and if using antidepressant medication, no changes in dose or type of 
medication during the past three months. Exclusionary criteria were: positive pregnancy test 
(urine dipstick test), currently breastfeeding, or planning to become pregnant during the nicotine 
patch study phase, physical limitations to participate in vigorous intensity exercise or sub-
maximal exercise testing (PAR-Q),28 current use (past three months) of smokeless tobacco 
products, or stop smoking medications or behavioral treatments, any medical condition 
precluding nicotine patch use, current or lifetime DSM-IV diagnosis of bipolar disorder, 
schizophrenia/other major thought disorder, and another person from the same household had 
enrolled. There was no upper cutoff for body mass index (BMI) if no other cardiovascular risk 
factors were present if BMI was >30. 
One hundred five individuals were screened by telephone, of which 30 (29%) were 
enrolled (Figure 1). Sixty-two of those not enrolled did not meet the study eligibility criteria and 
the primary reason was a CES-D score <16 (38/62, 61%). Others were medical exclusions (n=8), 
smoked infrequently (n=6), recent change in antidepressant medication (n=2), age (n=5), too 
physically active (n=1), or distance from exercise facility (n=2). Women not enrolled were given 
referral resources. 
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Procedures 
We used a randomized, two-group design with assessments completed at baseline, after 12 
weeks of treatment, and at six months post-target quit date (TQD). Participants were stratified 
according to current depression severity (baseline Patient Health Questionnaire [PHQ-9]29 score: 
mild/moderate vs. severe) and antidepressant medication use (yes/no) and randomly assigned to 
the exercise intervention group (EX, N=15) or to the health education contact control group (HE, 
N=15). The conditions were matched for wellness coach contact time and duration of treatment. 
Allocation to treatment conditions was unknown to the study staff or investigators prior to 
assignment, and participants completed baseline assessments prior to being informed of their 
allocation to treatment condition. A study coordinator blinded to allocation group conducted all 
follow-ups in-person. Participants received $25 for completing the baseline assessment and $50 
after completing each follow-up. All participants received a free 6-month YMCA membership 
(HE participants received this after the final assessment).  
For the biomarker analysis, participants were also asked for their written informed 
consent to provide a blood sample during the baseline visit and again at Week 12. A participant’s 
decision to participate in this aspect of the study did not affect enrollment in the pilot trial. All 30 
enrolled women provided consent to participate. They received an additional $25 for providing a 
blood sample at baseline and $50 for providing the Week 12 sample. 
Interventions 
For both conditions, the 12-week program comprised three 30-40 minutes individual-based 
sessions per week delivered by wellness coaches.30-32 At one session each week, participants 
received 15-20 minutes of smoking cessation counseling.  
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Smoking cessation counseling and pharmacotherapy  
The cessation counseling33 was identical for both conditions, except that for HE participants the 
use of exercise was not discussed as a strategy for managing depression, craving, or withdrawal 
symptoms. At Weeks 2 and 6, participants were mailed a 4-week supply of nicotine patches. The 
TQD was the first session of Week 3. At this visit, participants received instructions on using the 
patch. Patch dosing consisted of 21 mg/24 hours for four weeks, 14 mg/24hrs for two weeks, 
then 7 mg/24 hours for two weeks.33  Dosing was tailored based on cigarette consumption. Each 
week during the treatment phase, the coach assessed participants for side effects and adverse 
events associated with patch therapy, depressive symptoms and suicidality. 
HE  
Lectures, handouts, films, and discussions covered various women’s health and lifestyle issues, 
as used in previous trials.10,17 Attendance was recorded and missed appointments were re-
scheduled.  
EX 
The intervention was identical on exercise duration and intensity to that of Marcus and 
colleagues.17 The intervention manual (see supplemental material) incorporated language based 
on a study of consumer preferences for exercise interventions conducted among adults with a 
depression history.34  
All EX sessions were held at the YMCA, with the exception of four sessions which were 
conducted at a worksite fitness center. Participants engaged in exercise during each session and 
were encouraged to attend the YMCA on other days and/or to exercise at home. Attendance was 
documented and missed appointments were re-scheduled.  
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Exercise was gradually progressed from moderate to vigorous intensity.27 Target heart 
rates (using heart rate reserve) were determined from the baseline VO2 maximal exercise test.25 
Participants were instructed to work at a Rating of Perceived Exertion (RPE)35 of somewhat hard 
to hard, corresponding to moderate-vigorous intensity;25 RPE was monitored. 
Participants exercised on cardiovascular equipment of their choice and received 
supervision, reinforcement, and counseling from the coach. Sessions comprised of a 5-minute 
warm-up, 20-30 minutes of aerobic activity, and a 5-minute cool down with stretching.17 To 
reduce the time, the coach delivered the exercise counseling while the participant was engaged in 
exercise.36 The counseling included social cognitive theory-based37 assessment and 
problem-solving of exercise barriers, reinforcement (shaping) of exercise, and methods to 
enhance exercise self-efficacy – including guidance on exercise technique, intensity, and positive 
feedback30,38,39  delivered using a motivational interviewing counseling style. At the first session, 
participants were given a Kinetic Activity Monitor (KAM®).40 The KAM® is worn on the waist 
and provided feedback to participants on activity increases above resting metabolic rate, activity 
duration, and number of calories expended.   
Wellness coaches, training, and treatment fidelity  
The interventions were delivered by female ACSM-certified wellness coaches with a master’s 
degree in clinical psychology (HE) or bachelors’ degree in health education (EX). Coaches 
received six hours of training on the treatment protocols. Coaches used a written treatment 
manual containing an outline/script and checklist of critical topics to be covered.41 All sessions 
were audiotaped and reviewed with the coaches during weekly meetings to reinforce treatment 
fidelity, provide feedback, and conduct additional training. Fifteen percent of the sessions were 
randomly selected to be checked for the proportion of intended topics that were delivered.42 
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Coach adherence to the HE and EX manuals was 90% and 95% respectively, indicating high 
fidelity. 
Biomarker Methodology 
Laboratory analysis of inflammatory markers was conducted at the Mayo Clinic Translational 
Neuroscience Laboratory (Tye). Peripheral blood samples (5 mL) were collected from 
participants at the CRU and centrifuged immediately at 2,500 rpm for ten minutes. Serum was 
stored at -80˚ C for analysis. Serum levels of pro-inflammatory cytokines interleukin-6 (IL-6), 
tumor necrosis TNF-α and CRP serum levels were determined using commercially available 
enzyme-linked immunosorbent assays (ELISAs) in accordance with manufacture instructions 
(Life Technologies, NY). 
Measures 
Baseline characteristics  
A baseline questionnaire documented age, race/ethnicity, marital status, and education as well as 
Fagerström Test for Cigarette Dependence score.43   
Feasibility 
Data related to participant recruitment were collected, including the number of potential 
participants screened, and the number excluded for each of the specific inclusion/exclusion 
criteria. Study retention was based on the proportion of enrolled women completing follow-up 
assessments. Treatment adherence was based on the proportion of 36 sessions completed.   
Treatment acceptability 
At Week 12, participants completed the 10-item validated Consultation and Relational Empathy 
(CARE) measure to assess satisfaction with the coach.44 Each item was rated on a 5-point scale 
ranging from poor to excellent (range 10-50). At six months, participants were asked if they 
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would recommend the program to depressed women interested in quitting smoking (options: 
definitely would, probably would, unsure, probably would not, and definitely would not).  
Smoking status 
Seven-day point-prevalence, self-reported cigarette smoking status was obtained at Week 12 and 
at six month follow-up.33 A saliva sample was collected at each time point for cotinine analysis45 
using NicAlert test strips. We assessed use of nicotine replacement therapy because use would 
elevate the cotinine concentrations. At each time point, participants who self-reported no 
cigarette smoking (not even a puff) in the last seven days confirmed with a cotinine test strip 
value of 0 or 1 were classified as non-smokers.45,46  
Cardiorespiratory fitness 
Changes in cardio-respiratory fitness by treatment group served as a manipulation check. At 
baseline and Week 12, all participants underwent a symptom limited incremental treadmill test 
using the Bruce protocol.25 Participants were encouraged to continue the exercise protocol to 
maximal exertion, confirmed by a RPE of ≥17 on the Borg (6-20) scale or a respiratory exchange 
ratio (RER) of ≥1.10. Oxygen consumed (VO2), carbon dioxide produced (VCO2), and minute 
ventilation (VE) were measured by mouth piece and pneumotachograph (MedGraphics, St. Paul, 
MN) throughout exercise.47,48 The RER was calculated as VCO2/VO2. Manual volume 
calibration was performed with a 3 L syringe and gas calibration was performed with 
manufacturer-recommended gases of known concentration. All calibration procedures were 
accomplished immediately prior to each test. Data were averaged over the last 30 seconds of 
each stage. Peak VO2 was defined as the mean of the last 30 seconds of the exercise test. 
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Physical activity 
At baseline and the week after the last (Week 12) intervention session participants were asked to 
wear the MSR (model 145) accelerometer, a miniature universal data logger validated for 
objective physical activity assessment.49 Participants were asked to wear the device on a belt 
placed on their lower back during waking hours; four days of at least ten hours of wear was 
required for a valid assessment. Participants returned the device using a postage-paid envelope. 
MSR counts of total physical activity and sedentary time were summarized. 
Body mass index (BMI) 
Height and weight were recorded at baseline and at Week 12 using a calibrated scale. 
Depressive symptoms 
The PHQ-9 was used to assess depressive symptoms at baseline and at Week 12. This brief self-
report measure has been extensively validated29,50 and has excellent test-retest reliability (r=0.96) 
over a one-week period among samples of untreated patients.51,52   
Non-study treatments 
At Week 12 and six month follow-up, the study coordinator assessed participant use of 
concomitant stop smoking medication, antidepressant medication, and other depression 
treatment.  
Statistical Methods 
To assess the adequacy of the randomization, demographics were compared between treatment 
groups using the chi-square test for categorical variables or the two-sample t-test/rank sum test 
for continuous variables. The percentage of enrolled participants who completed the six month 
follow-up assessment (i.e., study retention) was compared between treatment conditions using 
the chi-square test (Fisher’s exact test). The mean number of treatment sessions attended was 
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compared across treatment conditions using a two-sample t-test (rank-sum). Indices of treatment 
acceptability were compared across treatment conditions using the chi-square test for program 
recommendation and the two-sample t-test (rank-sum) for CARE scores. The effect of treatment 
group on PHQ-9 score, BMI, cardiorespiratory fitness, and MSR total physical activity and 
sedentary time at Week 12 was evaluated using ANCOVA with the baseline score/value as a 
covariate.   
The biochemically confirmed seven-day point prevalence smoking abstinence rate at 
Week 12 and six month follow-up was summarized for each group (point estimate and 95% CI) 
and compared between treatment groups using a chi-square test (Fisher’s exact test). Using an 
intent-to-treat approach,53 missing data were classified as smoking. Analyses also controlled for 
the stratification variables (PHQ-9 depression severity, antidepressant medication use).  
A two-way ANOVA was used to determine the impact of the exercise intervention and 
participants’ Week 12 smoking status on CRP, TNF-α and IL6 levels. Outliers >2 SD from the 
mean were excluded and significance was set as p<0.05. 
Results 
Participants 
Tables 1 and 2 show the baseline characteristics by study condition. Participants were primarily 
White, college-educated, middle-aged women with obesity and about half were taking 
antidepressant medication. Baseline characteristics were comparable across treatment groups.  
Feasibility 
Figure 1 summarizes treatment completion and follow-up information. Treatment adherence was 
high in both groups. HE participants completed a mean (SD)=24.0 (10.0) sessions (range 5-36) 
and EX participants completed a mean of 26.0 (10.0) sessions (range 5-36), p=0.55. The average 
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proportion of sessions attended was 66% for HE participants and 72% for EX. Retention was 
also good, with 87% (13/15) of participants in both groups completing the six-month assessment. 
Treatment acceptability 
Satisfaction with the counseling provided by the coach was high for both treatment groups (mean 
CARE score = 38.0 ± 4.0 [range 30-40] for HE vs. 39.0 ± 3.0 [range 30-41] for EX, p=0.52). All 
participants in HE and 92% of participants in EX indicated they would “definitely” recommend 
the program to another female smoker with depression, p=0.31.   
Smoking status 
Based on intent-to-treat analysis, as expected, the EX condition was associated with significantly 
higher biochemically verified smoking abstinence rates (73% [11/15]) compared to HE (33% 
[5/15]) at Week 12; χ2=4.821, df=1, p=0.028 (Figure 2). No statistically significant differences 
between groups were detected at six-month follow-up (27% [4/15] for EX vs. 40% [6/15] for 
HE); χ2=0.600, df=1, p=0.439. When adjusted for PHQ-9 score and antidepressant medication 
use, p=0.035 at Week 12 and p=0.48 at six-month follow-up.   
No participants reported engaging in non-study depression or smoking cessation 
treatments or changes in their medical or psychological depression treatment at Week 12. At 
six-months, two participants in each group reported change in their depression treatment. 
Cardiorespiratory fitness 
After adjusting for baseline assessment, cardio-respiratory fitness (V02 max) was, as expected, 
greater for EX than HE participants at Week 12 (p=0.002; see Table 2).  
BMI, physical activity, and depression 
None of the additional outcome measures were significantly different for EX compared with HE 
Week 12 (Table 2). 
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Inflammation biomarkers 
No significant group or interaction effect was observed for CRP, TNF-α or IL6 for intervention 
and smoking status pre- and post-intervention (data not shown). When individual differences in 
biomarkers were compared (Week 12 minus baseline level), a significant group effect was 
observed for IL6 dependent on smoking status. As illustrated in Figure 3, IL6 levels increased 
significantly more (F [1, 9] = 5.631; p = 0.04) for smokers compared with those who quit at 
Week 12. A small portion of subjects had levels below detectable limits (no difference between 
groups). 
Discussion 
Vigorous intensity supervised exercise is feasible and enhances smoking cessation among 
depressed female smokers. This study addressed an important gap in the field. Little previous 
work10,11 evaluated exercise interventions for smoking cessation among depressed smokers or 
those with comorbid psychiatric disorders.16 Observed increases in cardiorespiratory fitness for 
EX participants compared with HE confirmed the study conditions were implemented as 
intended. Strengths of the study are developing the intervention with advice from community 
women, use of an experimental design with a credible active contact-control group, and inclusion 
of pharmacotherapy for both groups. The interventions were well-specified in treatment manuals 
and delivered with high fidelity. Also, the exercise intervention was implemented in a 
community YMCA setting, enhancing external validity.  
The exercise intervention appeared to benefit women only as long as it was active. 
YMCA data indicated that only two women in the exercise condition attended that facility after 
Week 12; of these, one exercised twice, another exercised 47 times. Thus, a key challenge for the 
field is to discover innovative and cost effective strategies to bolster long-term adherence, while 
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considering that supervised exercise is associated with better outcomes in studies of both 
depression54 and smoking cessation (see also Ussher et al.16 for review).55,56 Possible strategies 
include utilizing fitness trainers at the YMCA to reinforce participants for attendance and 
provide some level of supervised exercise, providing coach feedback and support via mobile 
technology such as text messaging or through newly available accelerometers that connect 
users,57,58 or tapping into natural support networks such as asking participants to bring someone 
with them to exercise.  
The reasons why the intervention did not differentially impact depressive symptoms are 
unclear especially given that exercise adherence was high and increase in cardiorespiratory 
fitness was achieved. However, over half of the sample was already being treated for depression 
with an antidepressant medication, limiting potential impact of exercise on depression severity. 
Additionally, we did not assess mood/depressive symptoms prior to enrollment, or if the women 
had treatment resistant depression. Over a 12-week intervention period, no participants reported 
changes in their depression treatment and only four reported such changes at six months, which 
could indicate they were functioning well despite ongoing or stable depressive symptoms. 
A novel finding indicates that IL6 levels were significantly elevated at Week 12, relative 
to baseline, for those women who continued smoking compared with those who quit. This 
preliminary evidence for increases in IL6 could be explored further in larger samples as a 
potential biological mediator of treatment efficacy.59,60 Although an interaction effect for 
smoking status by treatment was not observed, given the small sample size and with only one 
individual in EX continuing to smoke it is not possible to draw any clear conclusions at this 
stage.   
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This pilot has a number of shortcomings that should be noted. Like most pilot trials, the 
study findings are limited by the small sample size; however, considering the statistically 
significant results in some of our key variables, the findings are encouraging. Moreover, 
characteristics of our sample: women only, primarily Caucasian race and more severe depressive 
symptomatology, limit the generalizability. We inadvertently missed a substantial number of 
women who would have been eligible to participate if we used a less conservative CESD-10 
cutoff score of 10 recommended for general population samples. Two-thirds (38/62) of those 
screened but not eligible had a score of at least 10 but not as high as 16. Thus, in our definitive 
study which we plan, increasing the range of depressive symptoms among enrolled women and 
inclusion of a more diverse sample could substantially extend the reach of the exercise 
intervention.61 Despite these limitations, there is potential benefit of sustained, supportive, 
supervised exercise intervention for smoking cessation in depressed women, and this study 
points to new directions for future research.   
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Figure Legends 
Fig. 1: Participant flow. 
Fig. 2: Percentage of participants with biochemically confirmed, 7-day point prevalence 
smoking abstinence at the end of 12 weeks of treatment and six month follow-up by 
treatment group. 
Fig. 3: Change in levels of IL-6 from baseline to end of treatment by study group. 
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Table 1. Participant Baseline Characteristics by Treatment Group (N=30) 
 
 
Health Education 
Control (N=15) 
Exercise  
Intervention 
(N=15) 
 
 
p value* 
Age 
Range 
38.0 ± 11.0 
21-53 
37.0 ± 10.0 
25-53 
0.77 
 
Married/lives with partner 7 (47)  5 (34)  0.72 
White 14 (93)  13 (87)  0.54 
Education       0.72 
High school   1 (7) 2 (13)   
College 12 (80) 12 (80)   
Graduate school 2 (13) 1 (7)   
Employed  13 (87) 9 (60) 0.10 
Time to first cigarette < 5 
minutes (FTCD) 
6 (40)  7 (47) 0.84 
FTCD total score 
Range 
4.2 ± 2.0 
 1-7 
4.7 ± 2.2 
0-8   
0.55 
Taking antidepressant 
medication 
 
8 (53)  
  
9 (60) 
 
0.71 
Current psychiatric diagnosis 
(e.g., anxiety or depressive 
disorder)   
 
5 (33) 
 
6 (40) 
 
0.70 
 
 30 
 
FTCD = Fagerström Test for Cigarette Dependence.  Possible scores range from 0-10. 
*Two sample t-test or chi-square test as appropriate.  Data are reported as n (%) or mean 
± SD as appropriate.  
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Table 2. Baseline and End of Treatment (Week 12) Outcomes by Treatment Group 
 Baselinea  Week 12   
 
 
Measure 
 
Health Education 
Control 
 
Exercise 
Intervention 
Health 
Education 
Control 
 
Exercise 
Intervention 
 
 
p valueb 
PHQ-9 score 
(depression) 
Range 
 
11.6 ± 4.0 
3-18 
 
11.7 ± 5.4 
4-22 
 
7.0 ± 5.1 
0-17 
 
7.4 ± 4.5 
3-17 
 
0.90 
Body Mass Index 
Range 
V02 maxc 
Range 
30.0 ± 9.0 
19-45 
25.0 ± 5.0 
17-37 
31.0 ± 7.0  
21-42 
24.0 ± 5.0 
13-33 
30.0 ± 9.0 
19-48  
24.0 ± 4.0 
20-32 
31.0 ± 8.0 
21-44 
29.0 ± 6.0 
20-39 
0.77 
 
0.002 
 
V02 max predictedd 
Range 
98.0 ± 14.0 
74-125 
95.0 ± 19.0 
49-122 
97.0 ± 15.0 
66-123 
110.0 ± 16.0 
74-129 
0.002 
Overall physical 
activitye 
Range 
 
11452 ± 1687 
9192-13016 
 
12133 ± 3581 
7784-20304 
 
10924 ± 2057 
8013-15127 
 
11459 ± 4545 
7338-23664 
0.94 
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 Baselinea  Week 12   
 
 
Measure 
 
Health Education 
Control 
 
Exercise 
Intervention 
Health 
Education 
Control 
 
Exercise 
Intervention 
 
 
p valueb 
Sedentary timee 
Range 
327.2 ± 92.6   
202-469  
319.6 ± 131.6 
146-513 
286.6 ± 96.7 
154-477  
257.4 ± 114.0 
92-435  
0.56 
Note. For each treatment group N=15 at Baseline and N=13 at Week 12. Data are reported as mean ± SD. 
 
aP values > 0.05 for all variables when comparing health education and exercise interventions on the baseline 
assessment using a two sample t-test. 
bAnalysis of Covariance (ANCOVA) assessing change in measures.  For these analyses, the week 12 assessment 
was the dependent variable and treatment group and the baseline assessment were the independent variables.   
cVolume of oxygen consumed in mLs of oxygen per kilogram of body weight per minute.  
dThe prediction equation accounts for participant age. 
eData generated from Modular Signal Recorder (MSR) accelerometer. 
 
 
 
